Thymus Cancer Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH2037 | Last Updated On: Jun 20 2022 | Available Formats

> Global Thymus Cancer Market Expected to reach a high CAGR over the forecast period of 2022 to 2029 | DataM Intelligence

Global Thymus Cancer Market is segmented By Type (Thymic carcinoma, Type A, Type AB, Type B1, Type B2, Type B3), By Treatment (Chemotherapy(Carboplatin, Cisplatin, Ifosfamide, Others), By End-user (Hospitals, Clinics, Cancer centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Market Overview

The Global "Thymus Cancer Market" is expected to grow at a high CAGR  during the forecasting period (2022-2029).

Thymus cancer is a tumor formed on the outer surface originating from the epithelial cells of the thymus. The thymus is a small organ that is located in the upper chest under the breast region. Thymus cancer is uncommon cancer known for its association with the neuromuscular disorder myasthenia gravis and is found in 20% of patients with myasthenia gravis.

 

 

Market Dynamics

The major driving forces are the increasing prevalence of thymic cancer, growing demand for technological advancements, innovative treatments, and increasing government initiatives.

The increasing prevalence of thymic cancer is expected to boost the market. For instance, according to the Cancer.net (American Society of Clinical Oncology), less than one person per 1.5 million people develops thymic cancer. This means about 400 people per year acquires thymoma. However, the exact number is not known and may be increased using computed tomohy scans. Thymoma is very raunting for less than, 1andn the thymus. Thymoma and thymic carcinoma usually occurs in people between the ages of 40 and 60 but can occur at almost any age. Thus, the rising older population is likely to enhance the growth of the thymus cancer market.

The presence of ongoing research activities is expected to boost the market. 


The side effects related to the treatment of thymus cancer are expected to restrain the market. For instance, as per the American Cancer Society, radiation can damage the bone marrow leading to low blood counts. This can also lead to anemia (low red blood cell counts) and low white blood cell counts, which increases the risk of severe infections. Also, chest radiation therapy of the lungs. This may lead to trouble breathing and shortness of breath. This usually gets better after the radiation treatments stop, but sometimes the damage is long-term (or even permanent). Thus, the onset of side effects is likely to hamper the market.However, the high cost of treatment and the side effects of the treatment of thymus cancer is likely to hinder the growth of the thymus cancer market.

Market Segmentation

Based on the type, the global thymus cancer market is segmented into Type A, Type AB, Type B1, Type B2, Type B3, and thymic carcinoma.

The thymic carcinoma segment is expected to boost the market over the forecast period, owing to ongoing research activities. For instance, the European Organisation for Research and Treatment of Cancer started a single-arm, multicenter, phase 2 study of nivolumab in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (nivothym) in December 2017. The IFCT -The French Cooperative Thoracic Intergroup has started a randomized open-label adaptive phase III trial of belinostat to chemotherapy in patients with locally advanced potentially resectable thymic epithelial tumors (TET) in 2018. Further, the Sun Yat-sen University has commenced a phase 2 study of thymosin A1 during chemoradiotherapy for unresectable thymoma and thymic carcinoma in August 2018. The estimated study completion date is in August 2023. Thus, the presence of ongoing research activities on thymic carcinoma is driving the market.

Based on the treatment, the global thymus cancer market is segmented into surgery, radiation therapy, chemotherapy, etc.

Chemotherapy is further segmented into carboplatin (Paraplatin), cisplatin (Platinol), ifosfamide (Ifex), and others. The chemotherapy segment is expected to boost the market over the forecast period, owing to increased clinical trials. For instance, the National Cancer Institute has commenced a phase 2 pilot study to investigate the safety and clinical activity of the avelumab (MSB0010718C) in thymoma and thymic carcinoma after progression on platinum-based chemotherapy in 2017. The estimated study completion date is in September 2021. Also, the Georgetown University, in collaboration with Hackensack Meridian Health and Karyopharm Therapeutics Inc has commenced a  phase II, open-l of selinexor (KPT-330) in patients with advanced thymic epithelial tumor (TET) progressing after primary chemotherapy (SELECT) in 2017. The estimated study completion date was in December 2020. Thus, an increased number of clinical trials for the treatment of thymus cancer using chemotherapy drive the market.

Also, the radiation therapy segment is expected to grow at a high rate over the forecast period, owing to increased research and development activities by various universities. External beam radiation therapy (EBRT) is used to treat thymoma. EBRT delivers high-energy radiation to destroy cancer. In short, EBRT targets tumor cells explicitly and thus prevents damage to healthy cells. For instance, the Fudan University started an open-label, multi-center, randomized phase III study of adjuvant radiotherapy for stage II/III thymoma after complete resection in January 2018. The estimated study completion date is in December 2029. In collaboration with Beijing Hospital and 309th Hospital of Chinese People's Liberation Army, the Chinese Academy of Medical Sciences has commenced a multi-institutional, randomized phase III controlled trial of postoperative conformal radiotherapy for stage II-III b type thymoma in July 2013. The estimated study completion date is in July 2021. Thus, the presence of ongoing research activities undertaken by various universities is driving the market.

 

 

Geographical Analysis

Geographically, the global thymus cancer market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America was dominating the global thymus cancer market in 2018. It is estimated to hold a significant market size over the forecast period (2020-2027) owing to the increasing prevalence of thymic carcinoma and the presence of government organizations.

The increasing prevalence of thymic carcinoma is expected to boost the market over the forecast period. For instance, according to the American Cancer Society, although thymic tumor is the most common tumor in the anterior mediastinum (the front part of the chest cavity), overall, they are infrequent. They occur at a rate of  1.5 cases for every million people each year in the US. This is around  400 cases per year.

The presence of active government organizations in the region is expected to boost the market. For instance, the International Thymic Malignancy Interest group is an organization, which aims to promote the advancement of the clinical and basic science about thymic and other mediastinal malignancies and related conditions.

 

 

Competitive Landscape

The key players operating in the global thymus cancer market are Cellceutix Corporation, Merck & Co., Novartis AG, Boston Biomedical, Inc., (Sumitomo Dainippon Pharma Co., Ltd.), Tiziana Life Sciences PLC, Karyopharm, Nerviano Medical Sciences S.r.l., and Pfizer.

The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the thymus cancer market globally. For instance,

On June 1, 2018, Boston Biomedical, Inc., announced that it would present the new research evaluating the investigational compound napabucasin in the treatment of multiple cancers, including advanced gastric and gastroesophageal junction adenocarcinoma, metastatic pancreatic adenocarcinoma, and advanced thymoma and thymic carcinoma at the 2018 American Society of Clinical Oncology  Annual Meeting, held in Chicago from June 1-5, 2018.

 

Trending Topics

Cancer Stem Cell Therapy Market

Cancer CDK Inhibitors Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

Discount Applied



25% discount offer

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest